biostudies-literatureUnknown89(2)Ramanathan SThe Petre FoundationBrain FoundationSydney Research Excellence Initiative 2020 Neuroimmunology GroupThe National Blood Authority IVIg GrantNational Health and Medical Research CouncilThe National Blood Authorit IVIg GrantMultiple Sclerosis Research Australia<h4>Objective</h4>We characterised the clinical course, treatment and outcomes in 59 patients with relapsing myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination.<h4>Methods</h4>We evaluated clinical phenotypes, annualised relapse rates (ARR) prior and on immunotherapy and Expanded Disability Status Scale (EDSS), in 218 demyelinating episodes from 33 paediatric and 26 adult patients.<h4>Results</h4>The most common initial presentation in the cohort was optic neuritis (ON) in 54% (bilateral (BON) 32%, unilateral (UON) 22%), followed by acute disseminated encephalomyelitis (ADEM) (20%), which occurred exclusively in children. ON was the dominant phenotype (UON 35%, BON 19%) of all clinical episodes. 109/226 (48%) MRIs had no brain lesions. Patients were steroid responsJournal of neurology, neurosurgery, and psychiatry127-137https://www.ebi.ac.uk/biostudies/studies/S-EPMC5800335biostudies-literatureClinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.PMC5800335Merheb VPatrick EGill DWhite OBO'grady GThompson JClark DFraser CWare TCaruana PVucic SBarnett MHSubramanian GYiannikas CMohammad SMarriott MPilli DShah UCairns AFreeman JOuvrier RTantsis ECalvert SKothur KSpooner CAustralasian and New Zealand MOG Study GroupRamanathan SBrilot FBroadley SOrr CYiu EGrattan-Smith PHardy TWebster RChelakkadan SShuey NBarton JRyan MZou AParratt JBurrow JNosadini MRiminton DLopez JFung VSCLechner-Scott JAndrews PNguyen TKTea FThomas TReddel SWLing SGupta SRodriguez-Casero VButzkueven HScheffer ITroedson CMalone SDale RCHenderson APDRiney KfalseClinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.<h4>Objective</h4>We characterised the clinical course, treatment and outcomes in 59 patients with relapsing myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination.<h4>Methods</h4>We evaluated clinical phenotypes, annualised relapse rates (ARR) prior and on immunotherapy and Expanded Disability Status Scale (EDSS), in 218 demyelinating episodes from 33 paediatric and 26 adult patients.<h4>Results</h4>The most common initial presentation in the cohort was optic neuritis (ON) in 54% (bilateral (BON) 32%, unilateral (UON) 22%), followed by acute disseminated encephalomyelitis (ADEM) (20%), which occurred exclusively in children. ON was the dominant phenotype (UON 35%, BON 19%) of all clinical episodes. 109/226 (48%) MRIs had no brain lesions. Patients were steroid respons2018-01-01T00:00:00Z2018 Feb2026-06-17T07:06:18.956Z2026-06-17T03:10:24.854ZS-EPMC58003352914214510.1136/jnnp-2017-316880